Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics | $9.93 | -$13.23 | -0.57% | 387.3K | $628.9M | $8.04$24.17 |
| OWLS | Obook | $8.53 | -$10.98 | -0.56% | 791.9K | $1.7B | $8.25$90 |
| RYOJ | rYojbaba | $6.1 | -$3.02 | -0.33% | 533.5K | $102.6M | $1.81$11.43 |
| ATOM | Atomera | $2.93 | -$1.32 | -0.31% | 2.8M | $133.8M | $2.48$17.55 |
| GLGG | Themes ETF Trust - Leverage Shares 2x Long Glxy Daily ETF | $28.53 | -$12.25 | -0.30% | 44K | - | $12.38$45.8 |
| SLMT | Brera Holdings PLC | $6.61 | -$3.01 | -31.27% | - | - | - |
| OKLL | Tidal Trust II - Defiance Daily Target 2x Long Oklo ETF | $61 | -$25.34 | -0.29% | 2.5M | - | $16.09$169.96 |
| ATMV | AlphaVest Acquisition Corp | $9.38 | -$4.12 | -0.31% | 142K | $52.0M | $8$42 |
| QSU | Tidal Trust II | $13.35 | -$5.14 | -27.81% | - | - | - |
| NERV | Minerva Neurosciences | $4.87 | -$1.54 | -0.24% | 2.9M | $44.8M | $1.15$12.46 |
Related Articles
Featured Article
This Secret AI and Battery Stock Has Soared 148% in Just 5 Weeks
Neha Chamaria|Oct 8, 2025
Investors see SES AI as a potential Trump target. The company, meanwhile, is gearing up for a big event on Oct. 20.
Could Arcturus Therapeutics Be the Next Moderna?
Alex Carchidi|Mar 1, 2022
It's not likely, but it could still end up being a good investment.
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
Adria Cimino|Oct 15, 2021
The company disappointed last year, but things may be turning around.
This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More
Jeffrey Little|Oct 4, 2021
A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.
Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?
Keith Speights and Brian Orelli, PhD|Mar 14, 2021
There's at least one biotech that appears to be a potential contender.
Is Arcturus Therapeutics a Buy?
Alex Carchidi|Jan 12, 2021
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
Did You Miss Out on the Chance for Big Gains from Arcturus Stock?
Adria Cimino|Jan 6, 2021
The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
Why Is Everyone Talking About Arcturus Therapeutics Stock?
Zhiyuan Sun|Jan 5, 2021
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
Markets Ease Lower as Arcturus, Blink Charging Plunge
Dan Caplinger|Dec 29, 2020
Two top performers fell back to earth on Tuesday.
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus Vaccine
Eric Volkman|Dec 29, 2020
Investors obviously considered these to be underwhelming, however.
